The U.S. Food and Drug Administration has granted accelerated approval to the first CRISPR-based treatment for adults with severe sickle cell disease, a milestone for gene-editing medicine. The decision opens the door to a new option for patients who have long faced limited treatment choices.

The therapy uses CRISPR technology to target the genetic cause of the blood disorder, which can trigger painful crises, organ damage and life-threatening complications. Regulators said the approval applies to adults with severe forms of the disease, reflecting both the promise of the treatment and the need for continued monitoring.

The move marks a major step for gene therapy after years of research and clinical trials. It also raises questions about access, cost and whether patients across the U.S. will be able to benefit from a treatment built on one of biotechnology’s most closely watched tools.

For families affected by sickle cell disease, the approval offers hope after decades of uneven care and unmet medical need. Health experts say the real test will be whether the therapy proves durable, safe and broadly available in the months and years ahead.